Everything gathered so far on the Konted C10TX Pro handheld ultrasound distribution opportunity in Malaysia: the macro market, the full domestic + international competitive field, what everyone charges, and what everyone else is actually selling. Synthesized from six completed research files, no new research in this document.目前为止关于 Konted C10TX Pro 掌上超声马来西亚分销机会的全部研究整理：宏观市场、国内外完整竞争格局、各家的定价、以及大家实际在卖什么。本文档综合自六份已完成的研究文件，不含任何新增研究。
Narrow handheld ultrasound is growing at roughly 2x the rate of its own parent POCUS category (12.5% vs 7.1% CAGR), and an estimated ~4.7% of the total global ultrasound device market. Low penetration plus above-market growth is the classic signature of an early-innings category, not a saturated one.狭义掌上超声的增速大约是其母品类广义 POCUS 的两倍（CAGR 12.5% vs 7.1%），且推算约占全球超声设备总市场的 4.7%。低渗透率加上高于大盘的增速，是早期阶段品类的典型信号，不是饱和赛道的信号。
China's handheld ultrasound supply base (30+ active manufacturers) traces back to a 2017 national R&D policy priority, not organic market formation. Certifications (CE/ISO/FDA) are becoming table stakes, not differentiators, and product specs will keep converging.中国掌上超声供给端（30+ 家活跃厂商）的形成源自 2017 年的国家级研发政策扶持，不是自然市场演化的结果。认证（CE/ISO/FDA）正在变成入场标配而非差异化，产品参数也会持续被追平。
Malaysia is riding Southeast Asia's #1 position as China's medical device export destination, and separately, a Malaysia-China regulatory reliance pilot (Phase 2) that could cut MDA approval time from 45-220 working days to ~30, if applicable. That pilot window closes 2026-09-30, roughly 60 days from this report's date.马来西亚同时享有两个顺风：东南亚是中国医疗器械出口第一大目的地这个大趋势，以及一个马中监管互认试点（Phase 2），若适用可将 MDA 审批时间从 45-220 个工作日压缩到约 30 个工作日。这个试点窗口将在 2026-09-30 关闭，距本报告日期约剩 60 天。
The Konted case's 46.7-60% gross margin beats typical medical device distribution (15-30%), but a global investment-bank benchmark (BDA Partners) puts the median public-market medtech distributor gross margin at just 21.1%. Konted's number looks like an early-window premium, not the category norm.Konted 案例 46.7%-60% 的毛利率明显厚于一般医疗器械分销（15%-30%），但投行基准（BDA Partners）显示全球公开市场医疗器械经销商毛利率中位数只有 21.1%。Konted 这个数字更像早期窗口期的溢价毛利，不是这门生意的常态。
Traditional cart-based machines (RM50k-80k) require committee or loan approval and lock out most private clinics, GPs, vets, and aesthetic doctors. Konted's RM15k-20k band falls inside an individual doctor's own discretionary purchase power, compressing the decision chain to something a consumption-style marketing funnel can actually reach, which is exactly the lane a marketing-driven partner (not a traditional relationship-sales device trader) can occupy.传统台式机（RM5万-8万）需要委员会或贷款审批，把绝大多数私人诊所、GP、兽医、医美医生挡在门外。Konted 的 RM1.5万-2万 价位落在医生个人可自主决策购买的范围内，把决策链条压缩到营销漏斗真正能触达的程度，这正是营销驱动型合作伙伴（而不是传统关系型销售的器械贸易商）能够真正发挥价值的场景。
Global trend, size at every layer (global / China / Malaysia), how the business model is evolving, and the regulatory environment on both sides of the trade.全球趋势、每一层的市场规模（全球/中国/马来西亚）、生意模式如何演变，以及中马两国的监管环境。
Ultrasound imaging used to be radiology's exclusive asset: a machine costing hundreds of thousands of dollars, occupying a dedicated room, operated by a trained technician. Chip miniaturization, smaller probe arrays (Konted's C10TX Pro packs 192 elements / 64 channels into 193g), and cloud/app-side image processing have pushed ultrasound through the same decentralization that once moved computing from mainframes to personal computers: the device is leaving radiology and entering ER, anesthesia, obstetrics, cardiology, even general practice. This is a structural expansion of who uses ultrasound, not an incremental product upgrade.超声影像设备过去是放射科的专属资产：一台机器几十万到上百万美元，占地一个房间，需要专职技师操作。芯片微型化、探头阵列小型化（Konted C10TX Pro 用 192 elements / 64 channels 做到 193g）与云端/App 端图像处理能力提升，正在推动超声经历和当年"从大型机到个人电脑"类似的去中心化过程：设备正在离开放射科，进入急诊、麻醉、产科、心内科，甚至全科诊室。这是使用场景的结构性扩张，不是渐进式的产品迭代。
China's supply side did not form organically. In 2017, "portable handheld ultrasound" was named a priority direction in China's 13th Five-Year national key R&D plan (T1). National-level R&D programs typically come with funding, approval, and supply-chain support, which is the structural reason at least 30+ China manufacturers (Mindray, Wells Lead, Sonoscape, Konted's parent company, and others) are producing handheld ultrasound devices simultaneously today. The practical implication: price competition and product homogenization are the normal state of this category, not a temporary phase, and any narrative built on "a better probe" should assume a limited shelf life.中国供给端的形成不是自然市场行为。2017 年，"便携掌式超声"被中国科学技术部列入"十三五"国家重点研发计划优先方向（T1）。国家级研发计划通常伴随资金、审批、产业配套的系统性倾斜，这是今天至少 30+ 家中国厂商（迈瑞医疗、深圳华声、祥生医疗、Konted 母公司等）能够同时生产掌上超声的结构性原因。实际含义：价格战与产品同质化是这个赛道的常态，不是短期现象，任何建立在"我们的探头更好"之上的叙事，都应该假设保鲜期有限。
2026 Q1 saw Southeast Asia become China's #1 export destination for medical devices, at $2.601bn, up 14.66% YoY; Malaysia specifically was up 17.1% YoY (IB-18, T2). This is a double-edged trend: logistics, trade relationships, and policy friendliness are all improving for Malaysian partners, but it also means every other Chinese manufacturer watching the same trend line is likely eyeing Malaysia too. First-mover channel relationships and local service capability will matter more than "we brought this exact product in first."2026 年第一季度，东南亚成为中国医疗器械出口第一大市场，出口额 $2.601B，同比增长 14.66%；马来西亚具体同比增长 17.1%（IB-18，T2）。这是一把双刃剑：物流、贸易关系、政策友好度都在为马来西亚的合作伙伴改善，但也意味着看到同样趋势的其他中国厂商，大概率也会盯上马来西亚。先发的渠道关系与本地服务能力，会比"我们第一个把这个产品带进来"更重要。
Different research houses use different scopes (narrow handheld vs broad POCUS incl. cart-based portable vs all ultrasound devices) and different forecast years. Presented in layers below, not force-fitted into one "authoritative" number.不同研究机构的统计口径（狭义掌上超声 vs 广义 POCUS 含台式便携 vs 超声设备全品类）与预测年份不同，以下分层呈现，不强行拼接成单一"权威数字"。
| Tier层级 | 2025 size2025 年规模 | Forecast预测规模 | CAGR | Source来源 | Confidence置信度 |
|---|---|---|---|---|---|
| Narrow handheld ultrasound狭义掌上超声（Handheld） | $397M | $904M by 2032（2032） | 12.5% | Fortune Business Insights | T2 |
| Broad POCUS (incl. cart-based portable)广义 POCUS（含 cart-based portable） | $4.16B | $6.35B by 2030（2030） | 7.1% | Mordor Intelligence | T2 |
| Broad POCUS (alt. scope)广义 POCUS（另一口径） | - | $7.36B by 2030（2030） | 4.4% | Grand View Research | T2 |
| Global ultrasound device total (all forms, historical)全球超声设备总市场（全品类，历史区间） | $7.6B (2021)（2021） | - | 2.8% (2017-2021)（2017-2021） | 中商产业研究院 / Frost & Sullivan中商产业研究院 / Frost & Sullivan | T2 |
Cross-validation: $351M (2024) → $397M (2025) implies ~13.1% growth, closely matching Fortune Business Insights' own 12.5% CAGR (good internal consistency). A separate Chinese source (新思界产业研究中心) estimates $580M by 2028, which is in the same order of magnitude as a linear extrapolation of FBI's curve ($560-600M range by 2028), an independent EN/CN cross-check that lines up. Extrapolating the total ultrasound market's historical 2.8% CAGR to 2025 yields roughly $8.5B; narrow handheld ($397M) would then be about 4.7% of the total ultrasound device market, a small slice today, but expanding share far faster than the parent category (12.5% vs 2.8%).交叉验证：$351M(2024)→$397M(2025) 的年增速约 13.1%，与 Fortune Business Insights 自身给出的 12.5% CAGR 基本吻合，内部一致性良好。中国来源新思界产业研究中心估计全球掌上超声 2028 年规模 $580M，与 FBI 曲线线性外推至 2028（约 $560-600M 区间）量级一致，形成一次有效的中英文双侧交叉验证。若以全球超声设备总市场的历史 2.8% CAGR 外推至 2025 年，约为 $8.5B；据此推算，狭义掌上超声（$397M）约占全球超声设备总市场的 4.7%，今天仍是小众分支，但正以远超大盘的速度（12.5% vs 2.8%）扩张份额。
| Source来源 | Figure数字 | Confidence置信度 |
|---|---|---|
| 中商产业研究院 (citing Frost & Sullivan)中商产业研究院（引 Frost & Sullivan） | RMB 7.7bn (2015) → 11bn (2019) → 16bn (2024E), CAGR 7.7% | T2 |
| 华经产业研究院 | RMB 10.4bn (2021) | T2 |
| 灼识咨询 / CIC | RMB 9.92bn (2020) → 21.62bn (2030E) | T2 |
| 前瞻产业研究院 | RMB >13bn (2024) → 20.4bn (2029E), CAGR ~7.2% | T2 |
| 医械汇 | RMB 19bn (2022); largest single sub-category in China's medical imaging device market医学影像设备中最大细分品类 | T3 |
Five independent Chinese research houses converge on the same order of magnitude (RMB 10-20bn) and a tight CAGR band (7.2-7.7%), which is itself a credibility signal. 医械汇 specifically notes ultrasound is the largest single sub-category of China's medical imaging devices (by install count, since ultrasound is far cheaper than CT/MRI but installed far more densely). Assuming full penetration of ultrasound across ER, anesthesia, OB, cardiology, and endocrinology worldwide implies a theoretical ceiling around $27B, against an actual current market of roughly $500M, implying penetration of only ~1.9%: an extremely early stage.五个独立中国研究机构的数字虽然口径/统计年份不完全一致，但量级高度收敛（10-20bn RMB 区间）且 CAGR 高度收敛（7.2%-7.7%），这种独立信源的一致性本身就是一个可信度信号。医械汇特别指出超声是中国医学影像设备中最大的细分品类（按装机量而非单价衡量）。假设全球三甲医院的急诊、麻醉、妇产、心内、内分泌等科室全部渗透掌上超声，理论市场规模约 $27B，而当前实际规模仅约 $500M，渗透率约 1.9%，行业仍处于渗透曲线的最早期。
| 20252025 年 | 2033 (forecast)2033 年（预测） | Source / basis来源 / 依据 | |
|---|---|---|---|
| TAMMY diagnostic imaging device market, all modalities (X-ray/CT/MRI/ultrasound)马来西亚诊断影像设备市场（全模态天花板） | $322M | $615M | DataCube Research, CAGR 8.4%, T2 |
| SAMMY ultrasound devices (handheld+cart), report's own estimate马来西亚超声设备市场（掌上+台式，本报告推算切片） | $48.3M-$80.5M | $92.25M-$153.75M | Assumes ultrasound = 15-25% of TAM, based on China's "largest imaging sub-category" pattern; not an official MY breakdown假设超声占 TAM 的 15%-25%，基于中国"最大细分品类"的跨市场类比，非官方拆分数字 |
| SOMPartner's realistic obtainable share (12-24 months)合作伙伴现实可获取（12-24 个月） | RM 0.9M-8.75M / year, scenario-dependent, see below年，视情景而定，见下表 | Built on partner's own unit economics, highest confidence in this report基于合作伙伴真实单台经济模型，本报告置信度最高的一组测算 | |
Malaysia is described as "ASEAN's second-strongest private healthcare market" (Frost & Sullivan, T2): private hospital beds are growing from 19,000 to a projected 27,000 by 2028, and medical tourism drew 1.8M visitors and RM3.35bn in revenue in 2025. This private-healthcare segment is both expanding and more reachable by a marketing-driven distributor than public MOH procurement, which typically runs through tender/long-cycle paths.马来西亚是"东盟第二强私立医疗市场"（Frost & Sullivan，T2）：私立医院床位从 19,000 张增长至 27,000 张（至 2028），医疗旅游 2025 年吸引 1.8M 访客、创造 RM3.35B 收入。私立医疗板块本身就是一个持续扩张、且更容易被营销驱动型分销商触达的渠道（相对于公立 MOH 采购通常走招标/长周期路径）。
| Price assumption售价假设 | Landed cost到岸成本 | Unit gross profit单台毛利 | Gross margin毛利率 |
|---|---|---|---|
| RM15,000 (low end)（区间低值） | RM8,000 | RM7,000 | 46.7% |
| RM17,500 (report's assumed midpoint)（区间中位，本报告假设） | RM8,000 | RM9,500 | 54.3% |
| RM20,000 (high end)（区间高值） | RM8,000 | RM12,000 | 60.0% |
| Scenario情景 | Annual volume年销量假设 | Revenue年营收 | Gross profit年毛利 | ≈ Monthly GP折算月毛利 | Note备注 |
|---|---|---|---|---|---|
| A Conservative start保守起步 | 60 units/yr (5/mo)台/年（月均5台） | RM1.05M | RM570k | ~RM47.5k | Near-natural word-of-mouth pace, not yet systematized接近纯人脉/口碑转介速度，尚未系统化获客 |
| B Marketing-driven scale (yr 2)营销驱动放量（第2年） | 200 units/yr (16.7/mo)台/年（月均16.7台） | RM3.5M | RM1.9M | ~RM158k | Needs a systematic acquisition funnel, not referrals alone需要系统化获客漏斗，不能只靠转介 |
| C Regional scale (yr 3+)区域规模化（第3年+） | 500 units/yr (41.7/mo)台/年（月均41.7台） | RM8.75M | RM4.75M | ~RM395.8k | Needs a multi-state or even cross-border (SG/TH/ID) distribution network需要建立多州甚至跨境分销网络 |
Scenarios B and C land near or above Joel's usual Scaling Operator evaluation range for partner profit uplift (RM80-120k/month). Important caveat: these are scenario total gross profit numbers, not the incremental uplift attributable to marketing. The real uplift calculation still needs a confirmed natural sales baseline (what the partner could sell today purely on existing relationships/referrals, before any systematic marketing), i.e. the gap between Scenario A and a true zero-marketing baseline is not yet established. This is a key precondition to clarify before deal terms are discussed. Also for scale: at roughly USD 1 ≈ RM 4.2-4.5, the Malaysia SAM ($48M-154M) is on the order of hundreds of millions of ringgit, meaning even Scenario C's RM8.75M/yr is a low single-digit percentage of the estimated SAM or less. This is normal for an early, low-penetration, fragmented niche, not a red flag, but also not an "infinitely scalable" story.情景 B/C 的月毛利规模（RM158k-396k/月），落在 Joel 一般用来评估 Scaling Operator 机会时参考的 partner profit uplift 目标区间（RM80-120k/月）附近甚至以上。需要注意的是：这里呈现的是情景下的总毛利，不是"因营销合作而新增"的增量利润，真实的 uplift 计算还需要先确认合作前的自然销售基线（目前尚未确认合作伙伴在没有系统化营销介入前，纯靠现有人脉/转介能达到的自然销量），这是后续讨论合作条款时需要先厘清的一个关键前提。另外从量级看：以 USD 1 ≈ RM 4.2-4.5 概算，马来西亚 SAM（$48M-154M）相当于 RM 数亿元级别，即使在情景 C 的乐观假设下，RM8.75M/年也只是推算 SAM 的个位数百分比甚至更低。这符合一个早期、渗透率低、竞争分散的利基市场的正常特征，不是警讯，但也说明这不是一个"可以无限做大"的叙事。
Traditional cart-based machines run RM50k (used, foreign brand) to RM80k (new, "average specs" per partner feedback), a capital decision that typically needs a loan or committee approval for most private clinics, GPs, anesthesia departments, vets, and aesthetic doctors. Konted's RM15,000-20,000 price band falls inside a private clinic doctor's own discretionary purchasing power: the decision chain shortens from "committee / loan approval" to "the doctor decides on the spot." The same narrative is already playing out inside China: 智研咨询 notes portable ultrasound performance is closing in on cart-based machines, driving "grassroots healthcare upgrades," and Mindray's 2025 annual report cites an Anhui Lujiang county case where remote ultrasound solved a geographic-isolation-plus-talent-shortage problem, i.e. adding capability to a setting that never had it, not replacing an existing unit. If this reading holds, Malaysia's true comparable is a previously-unserved customer segment, not a replacement market for existing cart-based machines, and that kind of demand tends to be more marketing-responsive ("I didn't know I could have this") than a relationship-driven tender sale.传统台式机 RM50k（二手外国品牌）-RM80k（全新，"规格一般"）的价位，对绝大多数私人诊所、GP、麻醉科、兽医、美容医生而言是一次需要贷款或委员会审批的资本支出决策；Konted 的 RM15,000-20,000 价位，落在很多私人诊所医生个人可自主决策购买的范围内，决策链条从"委员会/贷款审批"缩短为"医生个人当场决定"。中国国内同样的叙事已经在发生：智研咨询指出便携式超声性能正在逼近台式机，驱动"基层医疗升级"；迈瑞医疗 2025 年报披露的安徽庐江县域医共体案例，正是通过远程超声解决"地理隔离+人才短缺"问题，本质上是把超声能力下放到过去没有这个能力的基层场景，而不是替换已有旧设备。如果这个判断成立，马来西亚掌上超声的真实可比对象，可能是一个此前不存在的新客群，而不是现有台式超声机的存量替换市场，这类需求通常营销敏感度更高（"我第一次知道我也可以拥有这个能力"），比传统关系型招标销售更适合营销驱动打法。
BDA Partners' 2025-04 report "SEA healthcare distribution: Delivering value" (T1, named investment bank, full 20-page report) directly rebuts the "distributors are worthless middlemen" investor assumption, and independently corroborates the moat discussion in Section 5.BDA Partners 2025 年 4 月发布的《SEA healthcare distribution: Delivering value》（T1，具名投行，20 页完整报告）正面反驳"经销商是无价值中间商"这个投资人常见误解，并独立佐证了第 5 节的护城河讨论。
| 2023 | 2029E | CAGR 2023-2029E | |
|---|---|---|---|
| SEA healthcare distribution (Medtech + Pharma, 6 countries: SG/MY/TH/VN/PH/ID)东南亚医疗健康分销（Medtech + Pharma 合并，6 国口径） | $18bn | $26bn | 7% |
| ↳ Medtech distribution↳ 医疗器械分销 | $3.0bn | $4.7bn | 9% |
| ↳ Pharma distribution↳ 药品分销 | $15.0bn | $21.3bn | 5% |
Malaysia's own Medtech distribution CAGR (2023-2029E) is 9%, in line with the regional 8-11% band. Healthcare spend as % of GDP in SEA (4.2%) is still well below developed-market average (10.3%), and the 65+ population share is set to double (8% in 2023 → 16% by 2050), structural tailwinds for long-term demand, not a short-term theme.马来西亚 Medtech 分销细分市场 2023-2029E CAGR 为 9%，与东南亚整体增速分布（8%-11%）一致。健康支出占 GDP 比例上，东南亚整体（4.2%）显著低于发达国家平均（10.3%），且人口结构正在快速老龄化（65+ 人口占比：2023 年 8% → 2050E 16%），这些都是支撑长期需求增长的结构性因素，不是短期题材。
| Investor objection投资人质疑 | BDA's rebuttalBDA 的反驳依据 |
|---|---|
| "Wouldn't manufacturers be more efficient going direct?""厂商自己直接铺渠道不是更有效率吗？" | Manufacturers generally lack the scale/infrastructure to build a channel in every local market; local distributors spread cost across multiple brands, creating real economies of scale.厂商普遍缺乏在每个本地市场建立渠道的规模与基础设施；本地经销商能横跨多个品牌摊薄成本，形成规模经济。 |
| "Aren't distributors interchangeable, can customers switch anytime?""经销商之间没有差异化，客户随时能换供应商？" | Market knowledge and channel infrastructure take real time and resources to replicate; distributors typically hold the local product license on behalf of the manufacturer, a real switching cost.经销商积累的市场专业知识、渠道基础设施需要大量时间与资源复制；经销商通常代表厂商持有本地产品牌照，形成真实的转换成本。 |
| "Isn't distributor value-add limited, margins naturally thin?""经销商的价值增量很有限，利润率天然被压低？" | Today's distributors go well beyond logistics: regulatory compliance, market access, tender management, financial management, after-sales, essentially acting as the manufacturer's local subsidiary.今天的经销商提供的服务范围早已超出"物流搬运"，包括监管合规、市场准入、招标管理、财务管理、售后服务，本质上是在扮演厂商的"本地子公司"角色。 |
| "Is cross-region platform synergy worth investing in?""跨区域平台化的协同效应值不值得投入？" | Yes: a single-region service provider can build a "flywheel" effect (info sharing, resource tilt to high-growth regions, single-market risk hedge).有，单一区域服务商能形成"飞轮效应"（信息共享、资源向高增长区域倾斜、单一市场风险对冲）。 |
Distributors often hold the local product registration license on behalf of the manufacturer. Even if a manufacturer wanted to cut out a distributor, it would first have to solve "whose name is the license under," a real time and relationship cost most manufacturers won't take on to remove a functioning distributor. This directly echoes Malaysia's Establishment License / Authorised Representative mechanism (Section 1.5), which naturally produces this kind of "license stickiness."经销商往往代表厂商持有本地产品注册牌照。即使厂商想甩开经销商自己卖，也要先解决"牌照挂在谁名下"这个问题，重建这套关系与牌照体系需要真实的时间成本，厂商通常不会为了甩开一个运转良好的经销商而承担这个风险。这直接呼应马来西亚的 Establishment License / 授权代表 (AR) 机制（见 1.5 节），客观上天然会产生这种"牌照粘性"。
| Medtech distributor (12 global public cos.)Medtech 经销商（12 家全球上市公司样本） | Pharma distributor (18 global public cos.)Pharma 经销商（18 家全球上市公司样本） | |
|---|---|---|
| Revenue CAGR (2019A-2023A, median)收入 CAGR（2019A-2023A，中位数） | 6.3% | 8.0% |
| Gross margin (LTM, median)毛利率（LTM，中位数） | 21.1% | 7.9% |
| EBITDA margin (LTM, median) | 10.5% | 3.3% |
| EV/EBITDA (LTM, public market公开市场, median) | 12.0x | 8.4x |
| EV/EBITDA (M&A deals并购交易, median) | 13.0x | 11.7x |
Medtech distributors trade at roughly a 31% valuation premium over Pharma distributors, for four reasons BDA cites: faster distribution-market growth (SEA 9% vs 5%), thicker gross margins (more complex product mix, more high-value-add services), more recurring revenue (maintenance contracts, consumable reorders), and stronger pricing power for reputable products even under public-sector price pressure. Sample includes Bunzl, Avantor, Henry Schein, Patterson Companies, AddLife, Shanghai Runda Medical, Ship Healthcare, AS ONE, Owens & Minor, Excelsior Medical, CHC Healthcare (Medtech); McKesson, Cencora, Cardinal Health, Sinopharm, China Resources Pharmaceutical, Apex Healthcare (Bursa: APEX, Malaysia-listed regional reference point) among others (Pharma).Medtech 经销商相对 Pharma 经销商的估值溢价约 31%，BDA 给出的理由：(1) 分销市场增速更快（东南亚 9% vs 5%）；(2) 毛利结构厚得多（产品组合更复杂、高附加值服务占比更高）；(3) 部分收入是经常性的（维保合同、耗材复购）；(4) 优质、有信誉的产品有更强的定价能力，即便面对公共部门的降价压力。样本含 Bunzl、Avantor、Henry Schein、Patterson Companies、AddLife、Shanghai Runda Medical、Ship Healthcare、AS ONE、Owens & Minor、Excelsior Medical、CHC Healthcare 等（Medtech）；McKesson、Cencora、Cardinal Health、Sinopharm、China Resources Pharmaceutical、Apex Healthcare（马来西亚上市，Bursa: APEX，区域参照点）等（Pharma）。
| Stage环节 | Gross margin毛利率区间 | Source来源 |
|---|---|---|
| China device manufacturer, high-value consumables leaders (e.g. 佰仁医疗/正海生物)中国医疗器械制造商，高值耗材头部企业（佰仁医疗、正海生物） | ~90% | China listed co. financials中国上市公司财报口径 |
| China device manufacturer, sector overall (2025 Q3)中国医疗器械制造商，整体板块（2025 Q3） | 47.9% | China listed co. financials中国上市公司财报口径 |
| China device manufacturer, equipment-class representative (福瑞股份)中国医疗器械制造商，设备类代表企业（福瑞股份） | 75% | China listed co. financials中国上市公司财报口径 |
| Global Medtech distributor (BDA Partners, public co. sample, LTM median)全球 Medtech 经销商（BDA Partners，公开上市公司样本，LTM 中位数） | 21.1% | BDA Partners |
| Konted case unit economics (partner's own data)合作伙伴实际经营的掌上超声单台经济模型 | 46.7%-60% | Partner 1st-party data合作伙伴一手数据 |
Manufacturers naturally run far higher margins than distributors, since they fold R&D/production fixed costs into the factory price. Distributors earn the spread of moving product from factory to end customer, and global public-market data puts that spread at roughly 20% for medtech. Konted's case (46.7-60%) is well above the global distributor median (21.1%), which doesn't mean the number is wrong (individual products/deals can reasonably diverge from an industry median, especially in an under-competed emerging niche), but it does mean Joel shouldn't assume every future product line will hold Konted-level margins. The ~20% industry median is probably the more prudent long-term planning baseline; Konted's number looks more like an early-window premium than the category's normal margin.制造商的毛利率天然远高于经销商（因为制造商承担了研发/生产的固定成本），经销商赚的是把产品从厂商手上搬到终端客户手上这段价值链的差价，全球公开市场数据显示这个环节的正常毛利率水平在 20% 出头。Konted 案例目前呈现的 46.7%-60% 毛利率，明显高于全球 Medtech 经销商的公开市场中位数（21.1%），这不代表 Konted 案例的数字有问题（个体产品/个体交易的毛利率本来就会跟行业中位数有差异，尤其是新兴细分品类议价空间更大），但提醒：不应该假设新公司未来所有产品线都能维持 Konted 案例这样的高毛利率，行业中位数（约 20%）可能是更审慎的长期规划基准，Konted 案例更接近"早期窗口期的溢价毛利"，不是"这个行业的正常毛利率"。
| Theme主题 | Logic逻辑 | Representative deal代表案例 |
|---|---|---|
| Geographic expansion地理扩张 | Leading distributors acquire into new high-growth SEA markets头部经销商收购切入新的高增长东南亚市场 | Zuellig Pharma acquired Ilmusys (Malaysia), 2024-07; Device Technologies (Australia) acquired Transmedic (Singapore), 2023-12Zuellig Pharma 2024-07 收购 Ilmusys（马来西亚）；Device Technologies（澳洲）2023-12 收购 Transmedic（新加坡） |
| End-market diversification终端市场多元化 | Companies outside healthcare enter via distributor acquisition原本不在医疗健康领域的企业通过收购经销商切入这个行业 | Suntory (Japan beverage giant) acquired NBD Healthcare (Thailand), 2024-03Suntory（日本饮料巨头）2024-03 收购 NBD Healthcare（泰国） |
| SEA market entry (by OEM)进入东南亚市场（厂商直接收购） | Manufacturers acquire local distributors for instant channel + market access厂商(OEM)直接收购本地经销商，一次性获得渠道与市场准入 | Kalbe (Indonesia pharma) acquired Alliance Pharma (Thailand), 2024-07Kalbe（印尼药企）2024-07 收购 Alliance Pharma（泰国） |
| Market consolidation市场整合 | Regional players roll up sub-scale distributors区域玩家通过"买入-整合"策略吞并次规模经销商 | everlife acquired mediva (Indonesia), 2023-05; DKSH acquired AcuTest (Malaysia), 2022-05everlife 2023-05 收购 mediva（印尼）；DKSH 2022-05 收购 AcuTest（马来西亚） |
| Platform building平台化建设 | PE investors build regional distribution platforms in a fragmented, sub-scale field财务投资人（PE）搭建区域分销平台，看中该行业次规模玩家众多、有整合空间 | Advantage Partners (Japan PE) invested in Pharmaforté (Malaysia), 2021-01; Everstone Capital invested in Chemophram/everlife (Malaysia), 2017-11Advantage Partners（日本 PE）2021-01 投资 Pharmaforté（马来西亚）；Everstone Capital 2017-11 投资 Chemophram/everlife（马来西亚） |
Both financial investors and regional consolidators are actively scanning sub-scale targets in this space right now. That's a risk (a better-capitalized consolidator could enter and compress the new company's independent runway) and a potential far-out exit reference point (if the new company builds a solid niche, being acquired by a regional platform/PE roll-up is a plausible long-term option, not something to plan around today, but worth having in the frame).这个行业目前处在一个财务投资人与区域整合者都在积极扫描次规模标的的阶段：这既是风险（意味着未来可能有资本更雄厚的整合者进场，压缩新公司的独立发展空间），也是一个潜在的远期退出路径参照（如果新公司真的把一个细分品类做扎实，理论上存在被区域整合者/PE 平台收购的可能性）。
Traditional cart-based ultrasound sits on a procurement-committee/tender model: high price (tens to hundreds of thousands of dollars), the buyer is a hospital procurement committee or radiology head rather than an individual doctor, sales cycles are long, and after-sales service (maintenance, calibration, parts) is a meaningful part of the margin. That model still dominates cart-based and large-hospital sales today.传统台式超声机的商业模式建立在几个特征上：单价高（数万至数十万美元）、决策方是医院采购委员会/放射科主任而非个人医生、销售周期长（往往涉及招标）、售后服务（保养、校准、备件）是利润的重要组成部分。这个模式至今仍是台式机与大型医院市场的主流。
| Western / premium camp (Butterfly, GE Vscan Air)西方/高端阵营（Butterfly、GE Vscan Air） | China / value camp (Konted + 30 others)中国/性价比阵营（Konted 及其他 30+ 家） | |
|---|---|---|
| Hardware pricing硬件定价 | USD 2,699-4,000 (Butterfly) / ~USD 3,595 (GE) | Markedly lower (Konted landed cost RM8,000 ≈ USD 1,700-1,900)显著更低（Konted 到岸成本 RM8,000 ≈ USD 1,700-1,900） |
| Software / cloud软件/云端功能 | Mandatory annual subscription强制年费订阅: Butterfly USD 299-3,500/yr; GE Vscan Air USD 595/yr | Lifetime free, no subscription终身免订阅 (Konted's core stated differentiator)（Konted 明确以此作为核心差异化卖点） |
| Revenue structure收入结构本质 | Hardware + recurring SaaS-like revenue (printer / ink-cartridge model)硬件 + 经常性 SaaS 式收入（类似"打印机卖便宜、卖墨盒赚钱"） | One-time hardware sale, bets on volume + geographic expansion一次性硬件销售，赌的是销量与地理扩张，不是复购订阅 |
| TCO | Significantly higher over multi-year use长期使用下 TCO 显著高于标价 | = one-time purchase price, predictable, no hidden cost= 一次性购买价，可预测、无隐藏成本 |
| Adoption friction采纳门槛 | Subscription creates extra friction in a price-sensitive market like MY private clinics订阅模式在价格敏感市场（如马来西亚私人诊所）会造成额外决策摩擦 | Outright buy better matches individual doctor / small-clinic purchase psychology一次性买断更符合个体医生/小诊所的采购心理 |
This split isn't accidental, it's the result of two different capital strategies: Western brands lean on higher brand premium and a more mature recurring-revenue investor narrative to lock in LTV via subscription; China's supply side, backed by policy and lower cost structures, competes on price and outright ownership. For a price-sensitive market with short private-clinic decision chains like Malaysia, outright buy has a structural adoption advantage, which is a real commercial logic behind Konted's positioning, not just marketing copy.这个分岔不是偶然的，而是两种资本策略的必然结果：西方品牌背靠更高的品牌溢价与更成熟的经常性收入投资者叙事，选择用订阅锁定 LTV；中国供给端在国家政策扶持下产能充沛、成本结构更低，选择用价格与买断模式抢占份额。对马来西亚这样价格敏感度较高、私人诊所决策链条短的市场，买断模式在采纳阻力上有结构性优势，这是 Konted 定位的一个真实商业逻辑，不只是营销话术。
Traditional cart-based procurement chains run: clinical need identified → department head evaluation → procurement committee sign-off → tender → finance approval → delivery/acceptance, a long, multi-party process measured in months to years. The RM15,000-20,000 handheld band compresses that chain to something close to a consumer-level decision: the clinic doctor personally evaluates and decides on the spot or within a short cycle. This is commercially significant: it means handheld ultrasound in the MY private-clinic segment can, in theory, be reached with a consumption-style marketing funnel (content seeding + online acquisition + conversion) rather than the door-to-door hospital-procurement relationship sales that most medical device categories require. This is precisely the setting where a Scaling-Operator-type partner can add real value, not every medical device category offers this possibility (large-hospital tender procurement has far lower marginal value for marketing).传统台式机的采购决策链条是：临床需求提出 → 科室主任评估 → 采购委员会立项 → 招标 → 财务审批 → 交付验收，链条长、涉及多方、销售周期以月甚至年计。掌上超声、尤其是 RM15,000-20,000 这个价位段，把决策链条压缩到接近消费级决策：诊所医生个人评估、当场或短周期内决定购买。这个变化的商业含义极其重要：这意味着掌上超声在马来西亚私人诊所这个细分市场，理论上可以用类似消费品的营销漏斗（内容种草 + 线上获客 + 转化）来触达，而不是必须依赖传统医疗器械行业"扫街拜访医院采购部"的关系型销售。这正是一个 Scaling Operator（营销驱动型合作伙伴）能够真正发挥价值的场景，不是每一个医疗器械品类都具备这种可能性。
Beijing Konted Medical Technology (manufacturer, est. 2014, Shenzhen/Beijing) ↓ CE MDR + ISO13485 + US FDA registration (2023) → 186-country sales network ↓ Factory price (not independently obtained; partner's landed cost RM8,000/unit incl. duty & logistics) Malaysia distributor (Joel's partner) ↓ Captures 46.7%-60% margin, depending on RM15,000-20,000 retail price ├─ Direct sales (clinic / doctor, short decision chain) └─ Possible sub-distributor / equipment-shop network (unconfirmed) End customer (private clinic / GP / anesthesia / ER / OB-GYN / vet / aesthetic doctor, etc.)Beijing Konted Medical Technology（制造商，2014 年成立，深圳/北京） ↓ CE MDR + ISO13485 + 美国 FDA 注册(2023) → 186 国销售网络背书 ↓ 出厂价（本报告未取得独立数字；合作伙伴到岸成本 RM8,000/台已含关税与物流） 马来西亚分销方（Joel 的合作伙伴） ↓ 捕获 46.7%-60% 毛利，视终端售价 RM15,000-20,000 而定 ├─ 直销（诊所/医生直接购买，决策链条短） └─ 二级经销/器材行网络（如有，未确认） 终端客户（私立诊所 / GP / 麻醉科 / 急诊 / 妇产科 / 兽医 / 美容医生等）
The Malaysia distributor's captured margin (46.7-60%) is markedly thicker than typical medical device distribution (usually 15-30%), because after-sales cost and long sales cycles on high-ticket cart-based machines erode margin there. This thicker margin isn't luck: it's the joint result of outright-buy pricing, a short decision chain, and relatively light after-sales needs (handheld maintenance is far lower than cart-based). This margin structure is the financial foundation for whether the business can support a genuine marketing-driven partnership.马来西亚分销方捕获的毛利率（46.7%-60%）明显厚于传统医疗器械分销（通常 15-30%，因为高客单价台式机的售后服务成本与长销售周期会侵蚀毛利）。这个厚毛利结构不是运气，而是买断制 + 短决策链条 + 相对轻量售后需求（掌上设备维护成本远低于台式机）共同作用的结果，这个厚毛利，正是能不能撑起一个真正的营销驱动型合作的财务基础。
As of this report's date (2026-08-01), the Malaysia-China regulatory reliance pilot's Phase 2 window has approximately 60 days left before it closes on 2026-09-30. Two independent uncertainties still need direct confirmation from MDA or a regulatory consultant, this month, not after deal terms are settled: (1) Konted C10TX Pro's current MDA registration status (submitted / under review / not started, unconfirmed as of this report), and (2) whether the product actually qualifies for the Phase 2 pilot.截至本报告日期（2026-08-01），马中监管互认 Phase 2 试点窗口距 2026-09-30 关闭还剩约 60 天。两个独立的不确定性需要 Joel/合作伙伴直接向 MDA 或专业监管顾问确认，且应该在本月内确认，而不是拖到合作条款谈定之后：(1) Konted C10TX Pro 当前的 MDA 注册状态（提交/审批中/尚未开始，截至本报告撰写时未确认）；(2) 该产品是否真的符合 Phase 2 试点资格。
2026 Q1: Southeast Asia is China's #1 medical device export destination, $2.601bn, +14.66% YoY; Malaysia specifically +17.1% YoY (Indonesia +27.4% highest, Philippines +9.6%). In H1 2024, 6 of the top-10 "Belt and Road" medical device export destinations were SEA countries, Malaysia among them (IB-19, T2). Trade relationships and policy friendliness between China and Malaysia are improving on this front, not deteriorating.2026 年第一季度，东南亚是中国医疗器械出口第一大市场，出口额 $2.601B，同比增长 14.66%；马来西亚具体同比增长 17.1%（印尼 +27.4% 最高，菲律宾 +9.6%）。2024 年上半年"一带一路"医疗器械出口十强目的地中，6 个是东南亚国家，马来西亚在列（IB-19，T2）。中马两国在医疗器械贸易层面的政策环境、物流基础设施都在向好，不是逆风环境。
Standard MDA registration runs 45-220 working days; ultrasound scanners are typically classified Class B or C (medium risk).标准审批时间为 45-220 个工作日；超声扫描仪在马来西亚通常归类为 Class B 或 C（中风险器械）。
| Phase阶段 | Window时间窗口 | Scope覆盖范围 | Applies to Konted?对 Konted 的适用性 |
|---|---|---|---|
| Phase 1 | 2025-07-30 → 2025-09-30 (ended)（已结束） | Confirmed IVD-only, explicitly excludes ultrasound / general imaging devices确认仅限体外诊断试剂（IVD），明确不含超声等一般/影像类设备 | Not applicable, and already closed不适用，且已经关闭 |
| Phase 2 "Joint Assessment Pilot"「联合评估试点项目」 | 2026-07-01 → 2026-09-30 (in progress)（进行中） | Expanded to "higher-risk medical devices or IVD, excluding Class A/Class I"扩大至"较高风险医疗器械或 IVD，不含 Class A/Class I" | May apply but not officially confirmed, ultrasound (Class B/C) theoretically falls within "Class II and above" but public materials don't explicitly name the category可能适用但未获官方明确确认，超声扫描仪（Class B/C）理论上落在"Class II 及以上"的范围内，但公开公告未点名列出超声类目 |
If Phase 2 applies, MDA approval time could compress from 45-220 working days to roughly 30 working days. As of this report's writing, no record has been found of Konted C10TX Pro holding any MDA registration in Malaysia, i.e. the product's legal-sale status is currently unconfirmed.Phase 2 若适用，MDA 审批时间有望从标准 45-220 个工作日压缩至约 30 个工作日。目前尚未找到 Konted C10TX Pro 本身在马来西亚 MDA 的任何已注册记录，即这个产品在马来西亚的合法销售资质状态，截至本报告撰写时是未确认的。
Malaysia's Ministry of Investment, Trade and Industry (MITI) published the "New Industrial Master Plan 2030, Medical Devices Industry" sectoral plan in 2023 (T1, official government industry planning document). 2022 trade data: exports RM31.1bn (2021 spiked to RM41.4bn on COVID demand, 2022 normalized), imports RM8.2bn.马来西亚投资贸易工业部（MITI）《New Industrial Master Plan 2030, Medical Devices Industry》Sectoral Plan，2023 年发布（T1，政府官方产业规划文件）。2022 年数据：出口 RM31.1bn（2021 年因疫情激增至 RM41.4bn，2022 正常化回落），进口 RM8.2bn。
| Category品类 | Value / share金额/占比 | |
|---|---|---|
| Export strength (MY's manufacturing edge)出口结构（马来西亚强项） | Gloves / masks手套/口罩类 | RM6.9bn (22.2%) |
| Needles / catheters / cannulas针头/导管/套管 | RM5.2bn (16.9%) | |
| Rubber gloves橡胶手套 | RM4.8bn (15.5%) | |
| Import weakness = Joel/Kang's opportunity zone进口结构（马来西亚弱项，即机会所在） | Instruments & appliances仪器与器械 | RM1.6bn (19.0%) |
| Needles / catheters / cannulas针头/导管/套管 | RM1.2bn (14.7%) | |
| Electro-diagnostic apparatus (typically incl. ultrasound)电子诊断设备（通常包含超声设备） | RM0.7bn (8.2%) | |
| Orthopedic devices骨科器械 | RM0.5bn (6.1%) | |
| Contact lenses隐形眼镜 | RM0.5bn (6.1%) |
Malaysia is the world's largest rubber-glove producer (67% of global supply), a completely different lane from small high-tech device trading. Top 5 import sources: US RM1.4bn (17.4%), China RM1.2bn (14.1%, already Malaysia's #2 device import source), Singapore RM1.0bn (11.9%), Germany RM0.8bn (9.7%), Japan RM0.7bn (8.9%). Government's own words (NIMP 2030, item 30): "Malaysia is highly dependent on imports of high-tech medical devices from other countries. As a result, rising healthcare demand has led to higher import volumes."马来西亚是全球最大橡胶手套生产出口国（占全球供应 67%），跟"小型高技术设备贸易"完全是两个不同的赛道。前五大进口来源国：美国 RM1.4bn(17.4%)、中国 RM1.2bn(14.1%，已是马来西亚第二大医疗器械进口来源国)、新加坡 RM1.0bn(11.9%)、德国 RM0.8bn(9.7%)、日本 RM0.7bn(8.9%)。政府原文明确写道（NIMP 2030 第 30 条）："马来西亚高度依赖从其他国家进口高技术医疗器械。因此，医疗保健需求的增加导致了更高的进口量。"
NIMP 2030's industry-presence matrix (Figure 5.2) rates Malaysia's local presence, High / Medium / Low, across five value-chain stages, for six medical device sub-sectors:NIMP 2030 用一张"产业存在感矩阵"（Figure 5.2），对马来西亚医疗器械六大细分领域，逐一评估从"研发"到"零部件制造"到"整机制造组装"到"销售与分销"到"售后服务"五个价值链环节的本地产业存在感（High/Medium/Low）：
| Sub-sector细分领域 | R&D研发 | Components零部件 | Assembly整机组装 | Sales & Distribution销售与分销 | After-sales售后服务 |
|---|---|---|---|---|---|
| Consumables (gloves/catheters)耗材（手套/导管类） | High | High | High | High | High |
| Surgical instruments / implants / clinical devices骨科植入物/牙科植入物类 | Medium | Medium | Medium | Medium | Medium |
| Health Equipment (ultrasound/MRI/blood management)Health Equipment（超声/MRI/血液管理设备） | Low | Low | Low | Low | Low |
| Point of Care (pulse ox/urine strips/IVD)Point of Care（脉搏监测/尿液试纸/IVD） | Low | Low | Low | Low | Low |
| Non/minimal invasive (glucose monitoring/smart surgical tools)血糖监测/智能手术工具 | Low | Low | Low | Low | Low |
| Tech-convergence devices (drug-eluting stents)药物洗脱支架 | Low | Low | Low | Low | Low |
This independently confirms, via a government industry-planning lens rather than an ads-observation lens, that Malaysia has essentially no strong local presence even in sales and distribution for Health Equipment and Point of Care, not just manufacturing. It cross-validates the Meta Ads Library finding in Section 2 that there's no well-serviced, trusted incumbent in this space, two completely independent data sources landing on the same conclusion.这独立证实（用政府产业规划视角，而非广告投放观察视角）：马来西亚在 Health Equipment 与 Point of Care 领域，不只是"制造"环节本地存在感低，连"销售与分销"这个 Joel/Kang 真正要切入的环节，本地产业存在感也被官方评为 Low。这跟第 2 节 Meta Ads Library 普查发现（马来西亚没有一个"服务好、有品牌信任度"的在位者）在两个完全独立的数据源上得出了同一个结论，交叉验证效果很强。
NIMP 2030, item 62, verbatim: "The rise of e-commerce has increased the circulation of unregulated and unauthorized medical devices in Malaysia, especially during COVID-19 when demand for pulse oximeters and test kits surged." This is close to a literal description of the risk zone a "digital-ad-driven + medical device + direct-to-end-customer" model sits in. Item 60 separately notes strict regulatory requirements "may pose a challenge for SMEs due to limited resources and expertise," the government's own admission of the compliance burden a small new company will face. This isn't a reason the path can't work (Section 2 confirms other companies are already running it in Malaysia), but it does mean product registration must be confirmed before any public marketing move, on every category, every time, not just the first product.NIMP 2030 第 62 条原文明确写道："电商的兴起增加了未受监管和未经授权的医疗器械在马来西亚的流通，尤其是 COVID-19 期间对血氧仪和检测试剂盒需求激增的时候。"这几乎是字面意义上在描述"数字广告驱动 + 医疗器械 + 直接触达终端"这个商业模式所处的监管风险区间。第 60 条同时指出严格的监管要求"可能对中小企业构成挑战，因为它们资源与专业能力有限"，这是政府自己承认的中小企业合规负担问题。这不代表这条路走不通（第 2 节已确认马来西亚已经有其他公司在这样做），但意味着产品注册资质必须先于任何公开营销动作到位，这条纪律需要在每一个新品类上都严格执行，不只是第一个产品。
Any entity importing or distributing medical devices in Malaysia must first hold an MDA Establishment License. Precondition: GDPMD (Good Distribution Practice for Medical Devices) certification, though a company can apply for the license with an interim GDPMD certificate and update once the formal certificate is issued. Channel: MeDC@St 2.0 online system. Standard processing: 21 working days. Validity is tied to the GDPMD certificate's validity (not a fixed term), renewable within one year of expiry.任何在马来西亚从事医疗器械"进口"或"经销"的实体，都必须先取得 MDA 颁发的 Establishment License。申请前置条件：必须先取得 GDPMD（Good Distribution Practice for Medical Devices）认证，由 MDA 认可的合格评定机构核发，可以先凭"临时 GDPMD 证书"申请。申请渠道：MeDC@St 2.0 在线系统。标准处理时间：21 个工作日。牌照有效期：与 GDPMD 证书的有效期挂钩，到期前一年内可申请续期。
Establishment License (company level): a company applies once, covering its status as an eligible distributor/importer in Malaysia. Per-product MDA registration (product level): every individual medical device product/model, regardless of supplier, in theory needs its own separate MDA registration (standard 45-220 working days) before it can be legally sold or advertised. Getting the Establishment License is only the entry ticket, it doesn't mean the company can freely list any new supplier's new product. Every new product line/supplier in theory triggers a fresh registration process, meaning multi-category expansion scales compliance workload roughly linearly (or worse), not "get the license once, add any category freely."Establishment License（公司层面）：一家公司只需要申请一次，覆盖"这家公司有资格作为经销商/进口商在马来西亚运营"这个身份。单个医疗器械产品的 MDA 注册（产品层面）：每一个具体的医疗器械产品/型号，无论来自哪个供应商，理论上都需要单独完成 MDA 注册流程（标准 45-220 个工作日），才能合法在马来西亚销售/宣传。新公司拿到 Establishment License 只是"拿到了入场券"，不代表可以立刻自由地把任意一个新供应商的任意一款新产品直接上架卖。每新增一条产品线/新供应商，理论上都要重新走一次产品注册流程，这意味着"多品类快速扩张"这个战略选项，在合规工作量与时间成本上是接近线性甚至更高的。
As a licensed distributor, ongoing legal obligations include: prominently displaying the license, maintaining complete distribution records, being the first point of contact for customer complaints (even when the defect originates at the China factory, the Malaysia distributor is the legal first responder), and proactively notifying MDA of business changes. Under the Medical Device Act 2012 (Act 737), Section 42(4), MDA can mandate a recall when a device poses material public health risk; the distributor can also self-initiate a voluntary recall. This means the distributor carries real after-sales and liability risk, it is not a purely "collect the spread and move on" light-asset business.作为持牌经销商，法定义务包括：醒目展示牌照、维护完整的分销记录、成为客户投诉的第一接触点（即使产品是中国厂商生产的，马来西亚终端客户遇到问题，第一个要负责处理的是本地经销商，不是原厂）、主动通知 MDA 任何经营信息变更。根据 Medical Device Act 2012（Act 737）第 42(4) 条，MDA 有权在医疗器械对公众健康构成重大风险时强制下令召回；经销商也可以主动发起自愿召回。这意味着经销商承担的是真实的售后与责任风险，不是纯粹"收钱转手"的轻资产生意。
Who's actually advertising handheld ultrasound in Malaysia, who's doing it internationally, and how the two groups differ in conversion path, category breadth, and price transparency.谁在马来西亚投放掌上超声广告，谁在国际上投放，以及这两批人在转化路径、品类广度、定价透明度上的差异。
A 20-keyword census (product-, brand-, and generic-device-angle, EN/ZH/Malay) across Meta Ads Library confirmed 5 real advertisers selling handheld/portable ultrasound in Malaysia. Two are direct comparables to Konted (same category, same ICP: clinics/doctors); three are adjacent or secondary. All ad counts, dates, and CTAs below are raw Meta Ads Library fields, not paraphrased.一次覆盖 20 个关键词（产品向/品牌向/泛医疗设备向，中英马来文）的 Meta Ads Library 普查，确认了 5 家在马来西亚真实销售掌上/便携超声设备的广告主。其中 2 家与 Konted 直接对标（同类目+同 ICP：诊所/医生）；3 家相邻或次要。以下广告数、日期、CTA 均为 Meta Ads Library 原始字段，非转述。
| Company公司 | Relevance关联度 | Active ads活跃广告数 | First seen最早开始 | FB followers粉丝数 | What they sell卖的是什么 | CTA | Price价格 |
|---|---|---|---|---|---|---|---|
| HATSBHealthcare Automation Technology Sdn Bhd | ★★★ direct, same model name直接同类目，型号撞名 | 9 | 2026-05-21 (~9wk)（~9周） | 1,479 | C10TX/C10TX Pro 3-in-1 pocket ultrasound + vein finder + wireless ECG + BP/SpO2/uroflowmeter (9-SKU vSARA remote-health IoT ecosystem)3合1口袋超声"C10TX/C10TX Pro"+静脉显影仪+无线心电图机+血压计/血氧仪/尿流率仪（vSARA 远程医疗 IoT 生态，9 款 SKU） | No button(5)/Learn more(2)/Get quote(1)/Sign up(1), all → fb.me native formNo button(5)/Learn more(2)/Get quote(1)/Sign up(1)，全部落地 fb.me 原生表单 | RM12,000-13,000 |
| MediShieldFirst Aid Supplies Sdn Bhd, agent for代理 Aurison | ★★★ direct, most systematic launch直接同类目，最系统化的上市打法 | 21 (~9 ultrasound + AED + hiring)（约9条超声+AED+招聘） | 2026-07-03 (~3wk)（~3周） | 3,133 | Aurison AI wireless handheld ultrasound (vascular/aesthetic multi-SKU) + AED defibrillators + first aid supplies (35-yr legacy company's newest line)Aurison AI 无线掌上超声（血管/美容多 SKU）+ AED 除颤器 + 急救用品（35 年老牌医疗器械公司新增产品线） | Send WhatsApp message (18/21) → api.whatsapp.comSend WhatsApp message（18/21）→ api.whatsapp.com | No public price, "first 30" RM11,000 gift-bundle promo instead无公开标价，用"前30名送RM11,000赠品"促销机制代替 |
| Reinkom Medical | ★★ secondary, ultrasound is 1 of 10 categories次要，超声仅是10大类之一 | 14 (only 1 = ultrasound)（仅1条为超声） | 2026-06-27 (~4wk)（~4周） | 11,706 | Comprehensive device distributor, 80+ countries; core = endoscopy/urology (cystoscopes/bronchoscopes/lithotripsy); ultrasound (RK-5LT/RK-5LR/UProbe) is newest addition (launched 2026-07)综合医疗器械分销商，全球80+国家有客户，主业为内窥镜/泌尿外科器械；超声（RK-5LT/RK-5LR/UProbe）是2026-07才新上线的最新产品线 | 100% Get Quote → fb.me | No public pricing anywhere官网+广告均无公开定价 |
| ADSS Group | ★ peripheral, "AI ultrasound" ad is actually a skin-analysis device边缘，"AI超声"广告实为皮肤检测仪 | 17 (2 mention "handheld ultrasound")（2条提及"Handheld Ultrasound"） | 2026-06-04 (~7wk)（~7周） | 112,185 | Aesthetic device wholesaler actively recruiting MY sub-distributors; HIFU/hair removal/lipolysis/LED phototherapy/pelvic floor chair etc. (6 major categories)医美设备批发 + 在马来西亚公开招募二级分销商（HIFU/脱毛/溶脂/LED光疗等一整套医美硬件，6大类） | Get quote (majority)（压倒性多数） → fb.me | No public pricing, "Become our distributor" model全线无公开定价，走"经销商招募"模式 |
| Dawei Ultrasound / Vet | ★★ adjacent, veterinary customer base not human clinics相邻，客群是兽医诊所而非人用诊所 | 1 each各1条 | Vet page: 2026-07-23 (just started)兽医页：2026-07-23（刚开始） | 6,828 / 87 | Veterinary portable color doppler ultrasound (L30i-VET/Y6/Elite/Slite) + veterinary digital X-ray兽医用便携彩超（L30i-VET/Y6/Elite/Slite）+ 兽用数字X光机 | Human page: Get Catalog→WhatsApp; Vet page: Get Quote→fb.me人用页 Get Catalog→WhatsApp；兽医页 Get Quote→fb.me | No public price无公开定价数据 |
HATSB's product page lists "C10TX" and "C10TX Pro", literally the same model names as Konted's product. This is very likely the same (or a highly similar) OEM hardware, already sold by another Malaysian company, at RM12,000-13,000, below the RM15,000-20,000 retail range Joel's partner assumed. If HATSB's landed cost is close to the RM8,000 baseline, their margin (33-38%) is notably thinner than the 46.7-60% Joel's report assumed, which could mean a price-war strategy, or a cheaper sourcing route. This needs direct confirmation with the Konted contact: (1) do they know HATSB exists, (2) is it really the same OEM hardware, and (3) does HATSB hold any exclusivity that could create a conflict. HATSB is not a shell company either: CEO is Dr. Saravanan Veloo, the company exhibited at "World of Health Care 2024," and its real core product is a remote-healthcare app ecosystem called vSARA, ultrasound is just one SKU in a broader hardware matrix meant to funnel users into that app, a different starting commercial logic than a pure hardware-margin distribution play.HATSB 官网产品页列出 "C10TX" 与 "C10TX Pro"，跟 Konted 的型号名字完全一样。这大概率是同一颗（或高度同源的）OEM 硬件，已经有另一家马来西亚公司在卖，价格 RM12,000-13,000，低于 Joel 合作伙伴假设的 RM15,000-20,000 零售区间。如果 HATSB 的到岸成本跟 RM8,000 基线接近，他们的毛利率（33%-38%）明显比假设的 46.7%-60% 薄，也可能是价格战策略，或者拿到了更便宜的货源。这需要直接跟 Konted 联系人核实：(1) 他们知不知道 HATSB；(2) 是否真的是同一颗 OEM 硬件；(3) HATSB 有没有独家协议在身。HATSB 不是空壳公司：CEO 是 Dr. Saravanan Veloo，公司参加过"World of Health Care 2024"行业会展，真正的核心产品是一整套叫 vSARA 的远程医疗 App 生态，超声只是导流硬件矩阵里的一个 SKU，跟纯硬件毛利分销的商业逻辑起点不完全一样。
Both direct competitors' ad campaigns are recent (3-9 weeks old at time of research), meaning this isn't a mature, settled channel, but a channel being validated by multiple parties at once. GP clinic chains also widely use "we offer ultrasound scans" as a marketing hook for their own patient packages, a separate finding from the keyword census's noise report, which further supports the "zero-to-one" demand read in Section 1: Malaysian GP clinics already recognize ultrasound as a patient-attracting capability, most just don't own the equipment yet, they refer out or outsource it.两家直接对手的广告投放都还很新（研究当时是3-9周），说明这不是一个成熟稳定的渠道，而是正在被多方同时验证的渠道。GP 诊所连锁也广泛用"有超声检查"当自身患者套餐的营销卖点，这是关键词普查噪音报告里的一个独立发现，进一步支持第1节"从零到一"的需求判断：马来西亚 GP 诊所已经认可"能做超声"是个对病人有吸引力的卖点，只是目前大部分靠转诊/外包，还没有自己买设备。
Butterfly, Clarius, GE HealthCare (Vscan Air), and Fujifilm Sonosite were checked directly by page ID across 8 countries (US/UK/AU/SG/AE/IN plus DE/FR for GE). All four run active, long-standing Meta ad programs.Butterfly、Clarius、GE HealthCare（Vscan Air）、Fujifilm Sonosite 四家用 page ID 直接核实横跨 8 个国家（美/英/澳/新加坡/阿联酋/印度，另加德/法核实 GE）的投放情况。四家全部在跑长期、活跃的 Meta 广告项目。
| Brand品牌 | FB followers粉丝数 | Countries tested (in this research)投放国家（本次测试范围） | Active ads活跃广告数 | Product focus产品聚焦 | Conversion path转化路径 |
|---|---|---|---|---|---|
| Butterfly Network, Inc | 21,161 | US only仅美国 | 21 | Butterfly iQ3 (human: ER/outpatient/full POCUS; separate vet line)Butterfly iQ3（人用：急诊/门诊/POCUS全科；另有独立兽医产品线） | Learn More → butterflynetwork.com (content-led, 1 Shop Now)（内容营销为主，1条Shop Now） |
| Clarius Mobile Health | 17,845 | US(25) / UK(21) / AU(5) | 51 (~12 unique creatives)（跨3国去重约12条独立创意） | HD3, T-Mode AI anatomy labeling, EF AI cardiac function, aesthetic ultrasound (filler guidance), primary careHD3、T-Mode解剖标注AI、EF AI心功能评估、医美超声（面部填充导针）、初级保健 | Learn More/Get Quote/Get Offer/Sign Up(webinar) → clarius.com |
| GE HealthCare (Vscan Air) | 187,620 (GE global page)（GE全球主页） | UK(22) / AU(19) / DE(16) / AE(2), US=0 | 59 | Vscan Air CL/SL, by specialty: cardiology/GP/ER/OB-GYN/physio/aestheticVscan Air CL/SL，按科室细分：心脏科/全科/急诊/妇产科/物理治疗/医美 | 3 different regional playbooks, see below三地区三套完全不同打法，见下 |
| Fujifilm Sonosite | 21,119 | US(28) / UK(15) / AU(15) / IN(11), SG/AE=0 | 69 | Sonosite MT (portable) / iLOOK (vascular access) / LX (46MHz ultra-high-freq) / PIV Assist AISonosite MT（便携）/ iLOOK（血管通路）/ LX（46MHz超高频探头）/ PIV Assist AI | Pure B2B: Download(clinical guide bait)/Learn More→"talk to rep", zero e-commerce, zero pricing纯B2B销售导向：Download（临床教育指南诱饵）/Learn More→"找销售代表"，完全不是电商直接下单 |
"Big brands don't do paid social" is false, all four run systematic programs with dedicated teams. But none has confirmed active advertising into Malaysia/Singapore/SEA yet, only GE has touched the region at all (2 ads in the UAE). This is a real open window, but 2nd-tier challenger brands (see 2.3) are already moving into adjacent markets (SG, AE, India) faster than the big four, meaning "the edge of the map is currently unclaimed" is a more accurate read than "the edge of the map will stay unclaimed.""大牌不做付费社媒"这个假设不成立，四家全部在做，而且有专门团队长期运营。但四家目前都还没有确认把广告打进马来西亚/新加坡/东南亚，只有 GE 触碰过这个区域（阿联酋2条广告）。这是一个真实存在的开放窗口，但二线挑战者品牌（见2.3）已经比这四家大牌更快地进入相邻市场（新加坡/阿联酋/印度），意味着"这块地图边缘目前没人占"比"这块地图边缘会一直没人占"更准确。
| Region区域 | Approach打法核心 | Landing page落地页 |
|---|---|---|
| EMEA (UK/AE/DE) | Content marketing + named doctor testimonials + educational webinars, on a dedicated microsite内容营销 + 医生证言 + 教育向webinar，走独立品牌微站 | vscan.rocks |
| ANZ | Direct e-commerce "Buy Now," by-specialty landing pages直接电商式"Buy Now"，按科室分别做落地页 | gehealthcare.com (main site product catalog) |
| Germany | Compliance-led, technical-spec-led, "we only supply professional medical channels"合规导向、技术规格导向，"我们只供应专业医疗渠道" | fb.me (native form, no dedicated page) |
GE tested a direct "Buy Now/Shop Now" push in Australia (May-Jun 2026) then walked it back to "See Details/Learn More" in later campaigns, likely after A/B testing conversion quality. Even a company at GE's scale hasn't settled whether direct e-commerce checkout works for a medical device, this is a useful reference point when deciding whether Konted's partner should mirror HATSB's e-commerce-style approach or MediShield's human-follow-up approach: there isn't a single proven answer yet, even among far larger players.GE 在澳洲市场先测过一版"Buy Now/Shop Now"直接促单打法（2026年5-6月），后续新campaign又切回了"See Details/Learn More"这种更软性的CTA，可能是转化率测试后的调整。连 GE 这种级别的公司，在"要不要用电商式直接促单打法卖医疗设备"这件事上也还没有定论，这在判断 Konted 合作伙伴该用 HATSB 式电商直销还是 MediShield 式人工跟进时，是个有用的参照：即便是体量远大得多的玩家，也没有一个已经验证的标准答案。
| Company公司 | Countries投放国家 | Price价格 | Positioning定位 |
|---|---|---|---|
| EagleView Ultrasound | UK/AE/AU/SG/US (global, same creative)（全球投放，同一套素材） | $2,899 official / $2,496 promo (22% off)官方标价 / $2,496 促销价（22% off） | 3-in-1 wireless dual-head, "No Subscription," running continuously since 2025-07 (1+ year), promo-calendar driven (Black Friday/Xmas/Cyber Week/"Thyroid Awareness Month")3合1无线双头探头，"No Subscription"卖点，自2025-07起持续投放超过1年，促销日历驱动（黑五/圣诞/跨年/甲状腺关注月） |
| DrSono Medical | US | 4 SKUs $1,099-$3,599 | Directly attacks the subscription model, quotes a real "ex-Butterfly user" negative review, explicit ROI math (CPT reimbursement codes, breakeven <8 weeks), FDA Class II + Karolinska University Hospital endorsement + 91→135 verified reviews, 4.7/5直接攻击订阅制，引用真实"前Butterfly用户"负评，具体ROI算法（CPT医保报销代码，回本周期<8周），FDA Class II认证+Karolinska大学医院背书+91→135条真实评论4.7/5 |
| CHISON Ultrasound Manufacturer | US/AE/AU/IN (factory account, direct)（工厂账号直营） | No public price, quote-only无公开定价，全线询价 | 30-yr, 100+ countries, CE & FDA certified; dual-track: B2B quote ads to clinics AND distributor-recruitment ads worldwide (explicitly offers "Marketing Support" to distributors); listed co. (STAR Market 688358)30年历史，服务100+国家，CE&FDA认证；双轨打法：对终端诊所的B2B询价广告 + 全球经销商招募广告（明确承诺给经销商"Marketing Support"）；上市公司（STAR Market 688358） |
EagleView and DrSono: 100% Shop Now / direct e-commerce checkout, zero ads land on an fb.me form, a genuine direct-purchase model with no human follow-up step. CHISON: 100% Get Quote → fb.me form → human follow-up, the same pattern as MediShield in Malaysia. All three keep their advertising strictly inside the ultrasound category, never crossing into other device types, a sharp contrast with every Malaysia-local advertiser (Section 4).EagleView 与 DrSono：100% Shop Now / 电商直接下单，零广告落地 fb.me 表单，是真正的直接购买模式，中间没有人工跟进环节。CHISON：100% Get Quote → fb.me 表单 → 人工跟进，跟马来西亚的 MediShield 是同一套打法。三家的广告严格限制在超声这一个技术类目内，从未跨到其他设备品类，跟每一家马来西亚本地广告主形成鲜明对比（见第4节）。
| Camp阵营 | Companies公司 | Category breadth品类跨度 | Price transparency定价透明度 |
|---|---|---|---|
| Regional trader/distributor (closest to Joel/Kang's new co identity)区域贸易商/经销商 （新公司最接近的身份） | HATSB, MediShield, Reinkom, ADSS, Dawei (all MY-local) | 100% multi-category100% 多品类 , ultrasound = one SKU/new category in a broader catalogue，超声只是各自产品目录里的一个SKU/新增品类 | Mixed, mostly quote-only (only HATSB meaningfully e-commerce-priced)混合，多数询价制（仅HATSB电商化程度较高） |
| Manufacturer/challenger brand (Konted's current positioning)制造商/挑战者品牌 （Konted 目前的定位） | EagleView, DrSono, CHISON (international, none in MY yet) | 100% single-category100% 单品类 (multiple ultrasound SKUs, never crosses to other device categories)（超声内部多SKU，但不跨到其他医疗器械） | Mixed, EagleView/DrSono highly transparent, CHISON fully quote-only混合，EagleView/DrSono高度透明，CHISON完全询价制 |
Category breadth tracks company identity (trader vs manufacturer) almost perfectly, not a random or company-by-company preference. A trader's core asset (channel relationships, warehousing/logistics, local certification capability) can carry unrelated product lines; a manufacturer is anchored to one R&D/supply-chain lane. Since the new company's agreed identity is "trader," the discussion in Section 4 goes further into what this actually means for positioning.品类跨度几乎完全跟随公司身份（贸易商 vs 制造商），不是随机的个体选择。贸易商的核心资产（渠道关系、仓储物流、本地认证能力）天然能承载互不相关的产品线；制造商则被自己的研发/供应链锁定在一个技术领域里。由于新公司谈定的身份是"贸易商"，第4节会进一步讨论这对定位意味着什么。
| Path路径 | Companies公司 |
|---|---|
| Native FB lead form (fb.me) → human WhatsApp follow-upfb.me 原生表单 → 人工 WhatsApp 跟进 | HATSB, CHISON, Reinkom, ADSS |
| Direct WhatsApp button直接 WhatsApp 按钮 | MediShield/Aurison, Dawei (human page) |
| Direct e-commerce checkout, no human step电商直接下单，无人工环节 | EagleView, DrSono |
| Pure B2B "talk to rep," no price, no self-serve纯B2B"找销售代表"，无价格，无自助下单 | Fujifilm Sonosite, GE (Germany variant) |
| Content marketing / soft lead-gen内容营销 / 软性获客 | Butterfly, GE (EMEA variant), Clarius (partial) |
Even companies with a real e-commerce-style shop page (HATSB has priced, in-stock listings) route their actual ad clicks to a lead form, not the shop page: the shop page functions as a separate discovery channel (branded search, WhatsApp-added contacts), not the ad-click destination. EagleView is the one clean exception where the e-commerce promise and the actual click path are fully aligned, click the ad and land directly on a checkout-ready product page.即使是有真正电商式商品页的公司（HATSB 有明码标价+库存的产品页），实际广告点击也导向表单，不是商品页：商品页更像是广告触点之外的独立入口（品牌词搜索、已加WhatsApp的联系人），不是广告点击后的第一落点。EagleView 是唯一一个"电商承诺"跟"实际点击路径"完全一致的例外，点击广告直接落地在可结账的商品页。
EagleView (soft): "No Subscription," "Free APP, No Subscription." DrSono (hard): "POCUS That Doesn't Send You a Bill Every Year," and a direct quote from a self-identified "Former Butterfly User": "I got tired of paying the regular ransom to keep the unit operational..." Validated in the US/UK market for 1+ year. No Malaysia competitor has run this angle explicitly yet, HATSB only hints at it via "Maintenance-free" copy. If Konted's pricing is outright-buy (it is), this is a validated, currently-unused positioning angle in Malaysia.EagleView（软性）："No Subscription"、"Free APP, No Subscription"。DrSono（强硬）："POCUS That Doesn't Send You a Bill Every Year"，并直接引用一位自称"前 Butterfly 用户"的负面评价。已在美/英市场验证超过1年。目前没有马来西亚竞品明确打这张牌，HATSB 只是隐约用"Maintenance-free"暗示。如果 Konted 的定价是一次性买断（确实是），这是一个已验证有效、马来西亚市场还没人用过的定位空间。
Five independent companies are betting on ultrasound-for-aesthetic-injection-guidance at once: GE (dedicated "Aesthetics Pack" preset), Clarius (facial filler needle guidance), EagleView (16/20MHz high-frequency probe marketed for "Comprehensive Puncture Guidance"), ADSS (adjacent, AI skin analysis), Ultrana (workshop-based aesthetic-injector training). This spans a top-tier global brand to a MY-adjacent aesthetic device wholesaler, not a coincidence. Worth flagging given Joel's existing Estique relationship, though no Malaysia ultrasound advertiser has run this angle yet.五家互不相干的公司同时押注"超声导引医美注射"：GE（专属"Aesthetics Pack"预设）、Clarius（面部填充导针）、EagleView（16/20MHz高频探头主打"Comprehensive Puncture Guidance"）、ADSS（相邻，AI皮肤分析）、Ultrana（工作坊式医美注射培训）。从顶级国际品牌到马来西亚相邻的医美设备批发商都在做，不是巧合。考虑到 Joel 已有的 Estique 关系，值得留意，虽然目前没有任何马来西亚超声广告主打过这张牌。
At least 4 mature markets (US/UK/AU, plus AE/India being tested by CHISON/EagleView) already have real participants running this exact playbook, ranging from GE/Fujifilm (century-old medtech giants) to DrSono/EagleView (evidently small-team, Shopify-style operations). Malaysia's HATSB/MediShield playbook (a generalist trader adds an ultrasound SKU, WhatsApp-driven human conversion) reads as a lower-configuration replica of this international playbook, not an original invention and not a unique Malaysian phenomenon. Separately, CHISON (a real factory, not a reseller) is already advertising directly into the US/AE/AU/India while simultaneously recruiting distributors worldwide with an explicit "Marketing Support" offer, meaning a new competitor could show up in Malaysia via a ready-made supplier playbook, not necessarily a homegrown one.至少4个成熟市场（美/英/澳，加上正在被CHISON/EagleView试探的阿联酋/印度）都已经有真实参与者在跑这套完全一样的打法，从GE/Fujifilm这种百年医疗器械巨头，到DrSono/EagleView这种明显是小团队/Shopify式操盘的创业公司，都在用。马来西亚HATSB/MediShield的打法（泛医疗器械贸易商加一条超声产品线，WhatsApp人工转化驱动）更像是这套国际打法的"低配复制品"，不是原创发明，也不是马来西亚特有现象。另外，CHISON（真正的工厂，不是经销商）已经在直接对美/阿联酋/澳/印度投广告，同时向全球招募经销商并明确提供"Marketing Support"，意味着马来西亚未来可能出现的新竞品，走的是一套现成的供应商打法模板，不一定是本地自己摸索出来的。
Everyone's actual or estimated price, with an honest confidence tier on every number, official pricing pages are not the same thing as third-party reseller estimates.每一家的实际或推算售价，每个数字都标注诚实的置信等级，官网标价跟第三方经销商估算不是一回事。
| Product / Brand产品/品牌 | Price价格 | Confidence置信度 | Note备注 |
|---|---|---|---|
| Konted C10TX Pro(Joel's partner's assumption)（Joel 合作伙伴假设） | RM15,000-20,000 retail零售, RM8,000 landed到岸成本, 46.7-60% margin毛利率 | 1st-party一手 | Highest confidence for Joel's own numbers, but the retail price itself is still an assumption, not yet market-testedJoel自己的数字置信度最高，但零售价本身仍是假设，尚未经市场检验 |
| HATSB C10TX | RM12,000 | T1 | Official website, 5 units in stock, 0%-interest installment offered官方网站，库存5台，提供零利息分期 |
| HATSB C10TX Pro | RM13,000 | T1 | Official website; same model name as Konted's product (see 2.1)官方网站；跟 Konted 产品同名（见2.1） |
| Aurison (MediShield) Pro/Ultra/Ultra Beauty | No public price无公开标价 | discovered | "First 30 customers" RM11,000 gift-bundle promo mechanism instead of a listed price用"前30名客户送RM11,000赠品"促销机制代替标价 |
| EagleView 3-in-1 | $2,899 regular官方标价 / $2,496 promo (22% off)促销价 | T1 | Official site官方网站 |
| DrSono Convex Pro | $1,499 (was $1,799) | T1 | Official site官方网站 |
| DrSono Linear Pro | $2,699 (was $2,999) | T1 | Official site官方网站 |
| DrSono Trolley Cart(accessory)（配件） | $1,099 (was $1,499) | T1 | Official site官方网站 |
| DrSono Tri-Scan Max(flagship 3-in-1)（旗舰3合1） | $3,599 (was $4,599) | T1 | Official site官方网站 |
| CHISON(all SKUs)（全线型号） | No public price, quote-only无公开定价，全线询价 | discovered | Listed company (STAR Market 688358), still runs a B2B quote model上市公司，仍走 B2B 询价制 |
| Butterfly iQ3 | $3,899 + mandatory sub. from $420/yr强制订阅起 $420/年 | T2 | Official pricing page + 3rd-party review cross-check; only brand surveyed with subscription NOT optional官网定价页+第三方评测交叉确认；本次调查里唯一"订阅不可选"的品牌 |
| Clarius HD3 | $3,500-4,400 + optional sub. $595/yr可选订阅$595/年 | T2 | Or one-time $2,500 buyout, select regions或一次性$2,500买断，限部分地区 |
| GE Vscan Air | ~$4,999 standard标准款 / ~$4,299 demo unit演示机 | T3 | 3rd-party distributor pricing (Henry Schein, Marcroft Medical), GE never publishes an official price, do not treat as a precise quote第三方经销商标价（Henry Schein、Marcroft Medical），GE官方从未公开定价，不要当作精确报价使用 |
| Fujifilm Sonosite(Portable tier)（Portable级别） | $20,000-$100,000 | T3 | 3rd-party distributor pricing; far above the handheld price band, explains why Sonosite runs pure B2B with no e-commerce第三方经销商标价；远高于掌上超声价格带，解释了为什么 Sonosite 走纯B2B、零电商 |
Platform / official 1st-party data, Meta Ads Library raw fields, official website pricing pages. Highest confidence.平台/官方一手数据，Meta Ads Library原始字段、官方网站定价页。置信度最高。
Credible 3rd-party, analyst estimates, cross-checked review sites. Medium-high confidence.第三方但可信来源，分析师估算、交叉确认的评测网站。中高置信度。
3rd-party reseller / distributor estimate, or unnamed industry commentary. Lower confidence, order-of-magnitude only, not an exact quote.第三方经销商侧面推算，或未具名行业评论。置信度较低，仅作量级参考，不是精确报价。
| SKU | Price价格 | Stock库存状态 |
|---|---|---|
| C10TX Pro (ultrasound)（超声） | RM13,000 | 5 in stock |
| C10TX 3-in-1 Pocket Ultrasound (ultrasound)（超声） | RM12,000 | Out of stock |
| CSE Expert 12-Lead ECG | RM5,500 | Add to cart |
| VAA2000 (vision screening)（视力检测仪） | RM7,000 | Add to cart |
| BP2A (blood pressure monitor)（血压计） | RM220 | Add to cart |
| SP02 (pulse oximeter)（血氧仪） | RM80 | Add to cart |
| VAA-2000 PCE (vision combo)（视力检测一体机） | POA | Call for pricing |
| Air Coach (indoor air quality)（室内空气质量监测） | POA | Call for pricing |
| Uroflowmeter (urine flow)（尿流率仪） | POA | Call for pricing |
Full SKU price range: RM80 to RM13,000.全线SKU价格区间：RM80至RM13,000。
| Model型号 | List price原价 | Mid-year promo中年促销价 | Gym-special promo健身房专案价 |
|---|---|---|---|
| MYHeart S Series | RM6,200 | RM5,999 | RM5,999 |
| MYHeart B&S Series | RM6,200 | RM4,999 | RM4,999 |
HATSB runs 2 active vein-finder ads, but that SKU does not appear on their 9-SKU shop page. Either it's pre-launch (ads running ahead of the e-commerce listing), WhatsApp/phone-quote-only for now, or the site simply hasn't caught up to the ad campaign (the same pattern MediShield showed earlier, ads live weeks before the website even mentioned the product). Not core to this report's conclusions, but a reminder that "what's in the ad" doesn't always equal "what's on the website" in this category.HATSB 在投放2条静脉显影仪广告，但这款产品没有出现在其9款SKU商品页里。可能是即将上市（广告先行造势）、目前只走WhatsApp/电话询价，或者官网更新滞后于广告投放（MediShield也出现过同样模式，广告先上线几周官网才提到产品）。不影响本报告核心结论，但提醒："广告里的产品"不总等于"官网上能买到的产品"。
As covered in Section 1.3: global public-market medtech distributor gross margin runs a median of 21.1% (BDA Partners), well below the Konted case's 46.7-60%. When planning future product lines beyond Konted, use the ~20% industry median as the prudent baseline, not the Konted case's number.如第1.3节所述：全球公开市场医疗器械经销商毛利率中位数是21.1%（BDA Partners），明显低于 Konted 案例的46.7%-60%。规划 Konted 以外的未来产品线时，应以约20%的行业中位数作为审慎基准，而不是 Konted 案例的数字。
Is ultrasound a wedge into a broader device catalogue, or a standalone focus? The answer splits almost perfectly by company identity.超声是打入更广泛器械组合销售的楔子，还是纯单一产品聚焦？答案几乎完全按公司身份划分。
| Company公司 | Other lines (from ads)其他产品线（广告发现） | Other lines (from website)其他产品线（官网发现） | Concurrently advertised?正在同时投放？ | CTA |
|---|---|---|---|---|
| HATSB | Vein finder, wireless ECG静脉显影仪、无线心电图机 | BP monitor, SpO2, vision screening (VAA2000/PCE), air quality monitor, uroflowmeter, 9 SKUs under the vSARA remote-health ecosystem血压计、血氧仪、视力检测仪(VAA2000/PCE)、空气质量仪、尿流率仪，9款SKU挂在vSARA远程医疗生态下 | YES是 , ultrasound(3)+vein finder(2)+ECG(3) running simultaneously since 2026-05-21, not sequential testing，超声(3条)+静脉显影仪(2条)+无线ECG(3条)自2026-05-21起同时投放，非先后测试 | All → same fb.me form regardless of product全部落地同一个fb.me表单，跟产品线无关 |
| MediShield / Aurison | AED defibrillators + sales/content hiring adsAED除颤器 + 销售/内容岗招聘广告 | First aid kits, burn care, emergency evacuation gear, medical supplies, first-aid training, stretchers/hospital beds, website has ZERO Aurison content急救箱、烧伤护理、安全应急疏散设备、医疗用品、急救培训、担架/医院病床，官网完全无Aurison内容 | YES, and parallel是，且并行 , ultrasound (~10 ads) & AED (~11 ads) same week, not "sell old line first then pivot"，超声(~10条)与AED(~11条)在同一周同时投放，不是"卖完老本行再切新品" | Send WhatsApp message, identical CTA and path for both product linesSend WhatsApp message，两条产品线CTA与落地路径完全一致 |
| Reinkom Medical | PEG feeding tubes, reusable ureteroscopes, reusable bronchoscopes, disposable tissue clips, reusable cystoscopes, endoscope camera systems, GI endoscopy systems, holmium laser lithotripsy, nasal-pharyngeal-laryngeal scopes, 9 different products each independently advertisedPEG造口管、可重复输尿管软镜、可重复支气管镜、一次性组织闭合夹、可重复膀胱镜、内镜摄像系统、消化道内镜系统、钬激光碎石仪、鼻咽喉软镜，9种产品各自独立投广告 | 10 major categories: rigid/flexible endoscopy, endoscopy instruments/consumables, disposable staplers, disposable care products, ultrasound (RK-5LT/RK-5LR/UProbe), ENT devices, anesthesia/respiratory equipment, electrosurgical platforms, colposcopy10大类：硬性/软性内窥镜设备、内窥镜器械/耗材、一次性吻合器、一次性护理用品、超声设备(RK-5LT/RK-5LR/UProbe)、耳鼻喉治疗仪、麻醉呼吸设备、电外科能量平台、阴道镜 | YES是 , 14 active ads across 9 products, ultrasound = only 1/14, lowest ultrasound-ad-share of any company surveyed，14条活跃广告覆盖9种产品，超声只占1/14条，是本次调查里超声占比最低的公司 | 100% Get Quote → fb.me |
| ADSS Group | Pelvic-floor EMS chair, HIFU face-lift, 3D skin analyzer, hair removal laser, cryolipolysis, LED phototherapy, microwave lipolysis盆底肌电磁椅、HIFU面部提升仪、3D皮肤分析仪、脱毛激光、冷冻塑身仪、LED光疗仪、微波溶脂仪 | 6 major categories: hair removal, AI products (incl. skin analysis), skincare, body contouring, tattoo removal, women's health; factory: 2,000㎡ cleanroom / 6,000㎡ industrial park / 160,000㎡ industrial zone / 10,000+ cases6大类：脱毛、AI产品(含皮肤检测)、皮肤护理、体型雕塑、纹身去除、女性健康；工厂规模2,000㎡无尘车间/6,000㎡产业园/160,000㎡工业园/10,000+案例 | YES是 , "AI Handheld Ultrasound" ad (actually a skin-analysis device, not diagnostic ultrasound) runs alongside 8 other aesthetic-device ads, no budget priority signal，"AI Handheld Ultrasound"广告（实为皮肤分析仪，非诊断超声）与另外8条医美设备广告平行投放，无预算倾斜迹象 | Get quote (majority) → fb.me; also Learn more, See detailsGet quote（多数）→fb.me；另有Learn more、See details |
| Dawei Ultrasound/Vet | Veterinary digital X-ray (RV-32B), veterinary dental X-ray兽用数字X光机(RV-32B)、兽用牙科X光系统 | Not deeply researched (lower priority), confirmed at least ultrasound + radiography (X-ray) as the two veterinary imaging categories未深挖（低优先级），确认至少超声+放射(X光)两大类兽医影像设备 | YES是 , vet ultrasound (L30i-VET/Y6/Elite/Slite) and vet X-ray rotate in the same ad set，兽医超声(L30i-VET/Y6/Elite/Slite)与兽医X光在同一广告集轮播 | Human page: Get Catalog→WhatsApp; Vet page: Get Quote→fb.me人用页Get Catalog→WhatsApp；兽医页Get Quote→fb.me |
| Company公司 | Other categories in ads?广告里有其他品类吗? | Other categories on website?官网有其他品类吗? | Verdict结论 |
|---|---|---|---|
| EagleView Ultrasound | NONE, 9+ months of continuous ads show only 2 ultrasound SKU variants + a suspected 3rd无，9个月+持续投放里只见2款超声SKU变体+疑似第3款 | NONE无 | 100% single-category单品类 |
| DrSono Medical | NONE other device category, but more ultrasound SKUs than expected无其他医疗器械品类，但超声品类内SKU比想象中更多 | Tri-Scan Max, Convex Pro, Linear Pro, Trolley Cart (accessory), Open Box Deals (clearance)Tri-Scan Max、Convex Pro、Linear Pro、推车配件、福利品 | 100% single-category单品类 (multi-SKU within ultrasound only)（超声品类内部多SKU） |
| CHISON | NONE, pure ultrasound manufacturer, 4 product-line categories, all ultrasound无，纯超声制造商，4大类全部是超声 | Same, confirmed no other medical device category同左，确认无其他医疗器械品类 | 100% single-category单品类 |
Every single Malaysia-local advertiser selling ultrasound (5/5 = 100%) is a multi-category trader, ultrasound is just one SKU in an existing catalogue. Every single international challenger brand advertising ultrasound (3/3 = 100%) is single-category, a manufacturer/brand anchored to one technology. This split maps almost perfectly onto company identity (trader vs manufacturer), not a random strategic choice: a trader's core asset (channel relationships, warehousing, local certification capability) can carry unrelated product lines; a manufacturer is anchored to its one R&D/supply-chain lane.在马来西亚本地投放超声广告的5家公司，无一例外全部是多品类玩家，超声只是他们各自庞大产品目录里的一个SKU。国际上真正"专精超声"的挑战者品牌（3家），反而全部是单品类，是锁定一个技术领域的制造商/品牌。这个划分几乎完全对应公司身份（贸易商 vs 制造商），不是随机的策略选择：贸易商的核心资产（渠道关系、仓储物流、本地认证能力）天然能承载互不相关的产品线；制造商则被自己的研发/供应链锁定在一个技术领域里。
HATSB's 9 CTA-tagged ads span 3 completely different product lines (ultrasound/vein finder/ECG), and all land on the same fb.me native form, just different button labels. MediShield's ultrasound ads (10/11) and AED promo ads (all of them) use the identical "Send WhatsApp message" CTA, literally the same funnel, same team, same ad budget pool, running an old (AED/first-aid) product line and a brand-new (ultrasound) product line side by side with zero differentiation in conversion path. Reading: multi-category traders don't build a separate funnel per new category, they plug new SKUs into whatever funnel machine already exists. This is the lowest-cost way to add a second product line, and MediShield is live proof it works, both lines were running simultaneously with no apparent cannibalization signal in the data collected.HATSB 9条CTA标注广告横跨3个完全不同的产品线（超声/静脉显影仪/心电图机），全部落地同一个fb.me原生表单，只是按钮文案不同。MediShield 的超声广告(10/11)和AED促销广告(全部)使用完全相同的"Send WhatsApp message" CTA，字面意义上是同一套漏斗、同一个团队、同一批广告预算，老产品线(AED/急救)和全新产品线(超声)并肩运行，转化路径零差异。解读：多品类贸易商不会为新品类单独建一套漏斗，而是把新SKU塞进已有的漏斗机器里。这是新增第二条产品线成本最低的方式，MediShield是活生生的证明，两条线同时投放，收集到的数据里没有出现明显的相互蚕食信号。
Pulling the market, competitive, pricing, and product threads together. This section surfaces data and questions for Joel, it does not render a verdict on whether to proceed.把市场、竞争、定价、产品四条线索拉在一起。本节 surface 数据和问题给 Joel，不对是否推进下判断。
Section 2 already showed 30+ China manufacturers competing on the same spec dimensions (probe count, waterproofing, battery life), gaps that will keep closing. Certifications (CE/ISO/FDA) are becoming table stakes, not differentiators. Three more plausible real defense points emerge from this research instead:第2节已经说明，30+ 家中国厂商在同一批参数维度上（探头数量、防水等级、电池续航）充分竞争，这些差距会持续被追平。认证（CE/ISO/FDA）正在变成入场标配而非差异化。本研究指向三个更可能的真实防御点：
Section 1.5's NIMP 2030 finding: no strong local presence exists even in sales & distribution for this category. The first company to build a well-serviced, warranty-backed reputation earns a trust asset that's genuinely hard to replicate quickly.第1.5节 NIMP 2030 的发现：这个品类在销售与分销环节本地存在感也是Low。第一个把本地质保/售后服务做扎实的玩家，能建立起后来者短期难以复制的信任资产。
Section 1.4's short decision chain is something traditional medical device traders don't have but a marketing-driven partner does, this is genuinely a different capability, not just more budget.第1.4节的短决策链条，是传统医疗器械贸易商不具备、但营销驱动型合作伙伴具备的能力，这是真正不同的能力，不只是更多预算。
Section 1.2's "zero-to-one" demand read means whoever teaches this previously-unserved segment "you too can own this" first accumulates brand memory and referral network, an asset that compounds.第1.2节"从零到一"的需求判断：谁先教育这批客群"你也可以拥有超声"，谁就积累先发的品牌记忆与转介网络，这是一种会复利的资产。
Not a moat: certification itself (it will become standard across 30+ competitors), or "we were first to bring this exact product to Malaysia" (since other China manufacturers are very likely to follow the same SEA export tailwind noted in Section 1.5, and CHISON's dual-track quote+distributor-recruitment playbook shows how fast a new entrant could show up via a ready-made supplier model).不构成护城河的是：认证本身（会在30+竞争者中逐渐变成标配）、以及"我们是第一个把这款产品带进马来西亚的人"这个叙事本身（因为第1.5节已指出，其他中国厂商很可能会跟进同样的东南亚出口顺风，而CHISON的双轨询价+经销商招募打法说明新竞品可能通过一套现成的供应商模式很快出现）。
Section 1.2's TAM-SAM-SOM analysis gives a clear read on magnitude: global narrow handheld ultrasound is about $397M today, Malaysia's estimated SAM (all ultrasound forms) is roughly $48-81M (2025), and the partner's realistic obtainable SOM, even in the optimistic Scenario C (500 units/yr), is RM8.75M/yr, a low single-digit percentage of the estimated SAM or less. This is not a "disrupt the whole medical imaging industry" story, it's a low-penetration, fragmented, but unusually healthy unit-economics niche opportunity. Scenario B (RM3.5M/yr revenue, ~RM158k/mo gross profit) is already a solidly-sized mid-tier partner business, the same order of magnitude as other Scaling Operator cases Joel has evaluated, not an outlier mega-opportunity, but not a trivial one either.第1.2节的TAM-SAM-SOM分析给出了一个清晰的量级判断：全球狭义掌上超声市场今天约$397M，马来西亚推算SAM（超声设备全形态）约$48M-81M（2025），而合作伙伴现实可获取的SOM，即使在情景C（500台/年）的乐观假设下，也只是RM8.75M/年，占推算SAM的比例是个位数百分比甚至更低。这不是一个能讲出"颠覆整个医疗影像行业"叙事的机会，而是一个渗透率低、竞争分散、但单台经济模型异常健康的利基型机会。情景B（RM3.5M/年营收，月毛利约RM158k）已经是一个相当扎实的中型合作伙伴生意规模，量级上与Joel现有其他Scaling Operator案例属于同一数量级，不是一个例外的巨大机会，但也不是一个可以轻视的小生意。
Section 1.5's dual regulatory uncertainty (product's own MDA status unknown + Phase 2 pilot eligibility unconfirmed, with only ~60 days left in the window as of this report's date) means any "when can we launch marketing" timeline discussion should be regulatory-confirmation-first, not marketing-plan-first. Concretely:第1.5节揭示的双重监管不确定性（产品自身注册状态未知 + Phase 2 试点资格未确认，且窗口仅剩约60天）意味着：任何关于"什么时候能正式启动营销"的时间线讨论，都应该先以监管确认为前提，而不是先谈营销打法再补监管手续。具体含义：
| Risk风险 | Likelihood可能性 | Impact影响 | Note备注 |
|---|---|---|---|
| Konted MDA registration not completed in time / not yet startedKonted MDA 注册未能及时完成或申请未启动 | Unknown, needs 1st-party confirmation未知，需一手核实 | High高 | Highest-priority open item优先级最高的待确认事项 |
| Phase 2 pilot eligibility doesn't cover ultrasound categoryPhase 2 试点资格不适用于超声类目 | Medium中 | Medium中 | Falls back to standard timeline, not fatal but affects launch date退回标准流程，非致命但影响时间线 |
| Another of the 30+ China manufacturers establishes formal MY distribution faster30+ 中国厂商中有其他玩家更早/更快建立马来西亚正式分销 | Medium中 | Medium-high中高 | Supports urgency of making local service/warranty real quickly支持"尽快把本地服务/质保做实"的紧迫性 |
| MY private-clinic willingness-to-pay overestimated ("zero-to-one" unverified)掌上超声在马来西亚私人诊所端的真实付费意愿被高估 | Unknown, no demand-side primary research yet未知，本报告未做需求侧一手验证 | High高 | Recommend small-scale market validation before large-scale commitment建议尽早做小范围市场验证，而非直接大规模投入 |
| Western brands (Butterfly/GE) later establish formal MY distribution西方品牌后续在马来西亚建立正式分销 | Low, no signal yet低，目前无迹象 | Low低 | Subscription model is a structural weakness in a price-sensitive market其订阅制模式在价格敏感市场天然弱势 |
| Working capital: no trading history, hard to get preferential trade financing, upstream cash-on-delivery vs downstream payment terms营运资金：新公司缺乏交易记录，难拿优惠贸易融资；备货现金压力 vs 下游账期挤压 | High priority高优先级 | High高 | How much of the startup capital covers inventory cash-flow buffer, not just the purchase principal?启动资金里，有多少是用来覆盖第一批库存的现金流缓冲（而不只是产品采购本金）？ |
| Compliance: company-level Establishment License + category-level MDA registration, multi-category expansion scales workload near-linearly合规：Establishment License（公司层面）+ 逐产品 MDA 注册（品类层面），多品类扩张=合规工作量线性增长 | High priority高优先级 | Medium-high中高 | Affects category-expansion speed影响品类扩张速度 |
| Regulatory visibility: digital-ad-driven device marketing is inherently more visible than traditional rep-visits-clinic sales监管可见度：数字营销驱动天然比传统关系型销售更容易被监管注意到 | High priority高优先级 | Every new category must re-clear this check每个新品类都要重新过一遍这道检查 | NIMP 2030 already names e-commerce-driven unregulated device circulation as an active problem (Section 1.5)NIMP 2030 已官方点名电商驱动的未受监管器械流通问题（见1.5节） |